Rita Medical to Present at Needham & Company's Fifth Annual Biotechnology and Medical Technology Conference
2006年6月10日 - 4:44AM
PRニュース・ワイアー (英語)
FREMONT, Calif., June 9 /PRNewswire-FirstCall/ -- RITA Medical
Systems, Inc. (NASDAQ:RITA), a publicly-traded medical device
company focused solely on cancer therapies, today announced that it
has been invited to present at Needham & Company, LLC's Fifth
Annual Biotechnology and Medical Technology Conference, which will
take place at the New York Palace Hotel. The Company is scheduled
to discuss its business strategy and historical financial
performance on Wednesday, June 14, 2006 at 1:30 p.m. Eastern Time.
Attendance at the conference is by invitation only. RITA Medical
will offer a live audio webcast of its presentation which may be
accessed at the Company's website at http://www.ritamedical.com/.
An archived replay of the presentation will also be available
approximately three hours following the live presentation and will
also be available at http://www.ritamedical.com/. About RITA
Medical Systems, Inc. RITA Medical Systems develops, manufactures
and markets innovative products for cancer patients including
radiofrequency ablation (RFA) systems and embolization products for
treating cancerous tumors as well as percutaneous vascular and
spinal access systems. The Company's oncology product lines include
implantable ports, some of which feature its proprietary Vortex(R)
technology; tunneled central venous catheters; and safety infusion
sets and peripherally inserted central catheters used primarily in
cancer treatment protocols. The radiofrequency product line also
includes the HABIB 4X resection device, which coagulates a
"surgical resection plane" and is designed to facilitate a fast
dissection in order to minimize blood loss and blood transfusion
during surgery. The proprietary RITA RFA system uses radiofrequency
energy to heat tissue to a high enough temperature to ablate it or
cause cell death. In March 2000, RITA became the first RFA company
to receive specific FDA clearance for unresectable liver lesions in
addition to its previous general FDA clearance for the ablation of
soft tissue. In October 2002, RITA again became the first company
to receive specific FDA clearance, this time for the palliation of
pain associated with metastatic lesions involving bone. The Company
also distributes LC Bead embolic microspheres in the United States.
The LC Bead microspheres are injected into selected vessels to
block the blood flow feeding a tumor, causing it to shrink over
time, and are often used in combination with radiofrequency
ablation (RFA). The RITA Medical Systems website is at
http://www.ritamedical.com/. DATASOURCE: RITA Medical Systems, Inc.
CONTACT: investors, Doug Sherk, , or Jennifer Beugelmans, both at
+1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, , all
of EVC Group, for RITA Medical Systems, Inc.; or Joseph DeVivo,
President and CEO of RITA Medical Systems, Inc., +1-510-771-0400
Web site: http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 5 2024 まで 6 2024
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Rita Medical Systems (ナスダック市場): 0 recent articles
その他のRita Medical Systems (MM)ニュース記事